There have been no open-market insider trades at Gain Therapeutics, Inc. in the last 12 months.
Zooming out by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters. On the institutional side, 50 funds reported holding GANX at the end of Q2 2026, and more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Aug 12, 2024 | Islam Khalid | Chair | Buy | 50,000 | $1.00 | $50K | SEC |
| Aug 12, 2024 | Mack Gene | CEO | Buy | 14,400 | $1.01 | $15K | SEC |
| Jul 1, 2024 | RICHMAN ERIC I | Director | Buy | 5,000 | $1.23 | $6K | SEC |
| Jul 1, 2024 | RICHMAN ERIC I | Director | Buy | 12,000 | $1.21 | $15K | SEC |
| Apr 1, 2024 | Riley Jeffrey Scott | Director | Buy | 30,000 | $3.86 | $116K | SEC |
| Dec 22, 2023 | Alder Matthias | CEO | Sell | 206 | $2.46 | $507 | SEC |
| Dec 14, 2023 | Alder Matthias | CEO | Sell | 1,820 | $2.50 | $5K | SEC |
There were no open-market insider trades in GANX in the last 12 months. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
50 investment managers reported holding GANX in SEC Form 13F filings for Q2 2026.
No congressional trades in GANX were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).